adagrasib,Pembrolizumab,Axitinib,gefitinib
mirati,merck,Pfizer,Astrazeneca
['key,note,426', 'key,note,42', 'durva', 'gefitinib', 'mirati']
 that is reasonable but regarding combo studies, codebreak pd-1 combo (wclc22) median 50+ days to onset, keynote-426 median time to onset 84 days, durva+gefitinib phase 1 study median onset 51 days... so it seems quite disingenuous for mirati to claim victory on liver tox here
Into ovens and baking